Test dell'immunoterapia con nivolumab e ipilimumab con o senza il farmaco mirato cabozantinib nel carcinoma rinofaringeo ricorrente, metastatico o incurabile
Studio randomizzato di fase 2 su nivolumab e ipilimumab con o senza cabozantinib in pazienti con carcinoma rinofaringeo avanzato in progressione dopo trattamento con platino e immunoterapia
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVE:
I. To determine if the progression-free survival (PFS) of the triplet combination (cabozantinib S-malate, nivolumab, and ipilimumab [CaboNivoIpi]) is more favorable than the doublet (nivolumab and ipilimumab [NivoIpi]).
SECONDARY OBJECTIVES:
I. To compare safety and tolerability between the two arms (Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0.).
II. To compare overall response rate (ORR) between the two arms via both Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune-modified Response Evaluation Criteria in Solid Tumors (iRECIST) criteria.
III. To compare overall survival (OS) between the two arms. IV. To assess response by primary or acquired PD-1/L1 inhibitor resistance in the prior line of therapy.
EXPLORATORY OBJECTIVE:
I. To evaluate molecular and immunologic predictors of response (Epstein-Barr virus [EBV] viral load; PD-L1 score) between arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI) and collection of blood samples throughout the trial.
ARM B: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 and cabozantinib S-malate orally (PO) daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may continue with cabozantinib S-malate after 2 years per treating investigator. Patients undergo CT or MRI and collection of blood samples throughout the trial.
After completion of study treatment, patients are followed up every 8-12 weeks until progression of disease occurs or a new non-protocol anti-cancer therapy is initiated and then every 6 months for up to 2 years.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
California
-
Irvine, California, Stati Uniti, 92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Los Angeles, California, Stati Uniti, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Stati Uniti, 90020
- Keck Medicine of USC Koreatown
-
Los Angeles, California, Stati Uniti, 90033
- Los Angeles General Medical Center
-
Newport Beach, California, Stati Uniti, 92663
- USC Norris Oncology/Hematology-Newport Beach
-
Orange, California, Stati Uniti, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Stati Uniti, 94304
- Stanford Cancer Institute Palo Alto
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30308
- Emory University Hospital Midtown
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Caldwell, Idaho, Stati Uniti, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Stati Uniti, 83814
- Kootenai Health - Coeur d'Alene
-
Nampa, Idaho, Stati Uniti, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Post Falls, Idaho, Stati Uniti, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Stati Uniti, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern University
-
Chicago, Illinois, Stati Uniti, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Stati Uniti, 60612
- University of Illinois
-
Danville, Illinois, Stati Uniti, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Stati Uniti, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Effingham, Illinois, Stati Uniti, 62401
- Carle Physician Group-Effingham
-
Evanston, Illinois, Stati Uniti, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Geneva, Illinois, Stati Uniti, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Stati Uniti, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Glenview, Illinois, Stati Uniti, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Stati Uniti, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Harvey, Illinois, Stati Uniti, 60426
- Ingalls Memorial Hospital
-
Highland Park, Illinois, Stati Uniti, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Lake Forest, Illinois, Stati Uniti, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Stati Uniti, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Stati Uniti, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
Orland Park, Illinois, Stati Uniti, 60462
- University of Chicago Medicine-Orland Park
-
Orland Park, Illinois, Stati Uniti, 60462
- Northwestern Medicine Orland Park
-
Urbana, Illinois, Stati Uniti, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Stati Uniti, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Iowa
-
Ankeny, Iowa, Stati Uniti, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive, Iowa, Stati Uniti, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Stati Uniti, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Stati Uniti, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Stati Uniti, 51503
- Methodist Jennie Edmundson Hospital
-
Council Bluffs, Iowa, Stati Uniti, 51503
- Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ
-
Des Moines, Iowa, Stati Uniti, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Stati Uniti, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Stati Uniti, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Stati Uniti, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Stati Uniti, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02111
- Tufts Medical Center
-
-
Minnesota
-
Bemidji, Minnesota, Stati Uniti, 56601
- Sanford Joe Lueken Cancer Center
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63128
- Mercy Hospital South
-
-
Montana
-
Anaconda, Montana, Stati Uniti, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Stati Uniti, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Stati Uniti, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Stati Uniti, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Stati Uniti, 59901
- Logan Health Medical Center
-
Missoula, Montana, Stati Uniti, 59804
- Community Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Stati Uniti, 68114
- Oncology Associates PC
-
Omaha, Nebraska, Stati Uniti, 68114
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
-
-
New Jersey
-
Basking Ridge, New Jersey, Stati Uniti, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, Stati Uniti, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Stati Uniti, 07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Commack, New York, Stati Uniti, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Stati Uniti, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, Stati Uniti, 11553
- Memorial Sloan Kettering Nassau
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Stati Uniti, 28204
- Novant Health Presbyterian Medical Center
-
Huntersville, North Carolina, Stati Uniti, 28078
- Novant Health Cancer Institute - Huntersville
-
Matthews, North Carolina, Stati Uniti, 28105
- Novant Health Cancer Institute - Matthews
-
Mooresville, North Carolina, Stati Uniti, 28117
- Novant Health Cancer Institute - Mooresville
-
-
North Dakota
-
Bismarck, North Dakota, Stati Uniti, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Stati Uniti, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Stati Uniti, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45220
- Good Samaritan Hospital - Cincinnati
-
-
Oklahoma
-
Lawton, Oklahoma, Stati Uniti, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Stati Uniti, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Ontario, Oregon, Stati Uniti, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Stati Uniti, 97239
- Oregon Health and Science University
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Medical University of South Carolina
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Stati Uniti, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Virginia
-
Richmond, Virginia, Stati Uniti, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Stati Uniti, 23298
- VCU Massey Comprehensive Cancer Center
-
-
West Virginia
-
Morgantown, West Virginia, Stati Uniti, 26506
- West Virginia University Healthcare
-
Parkersburg, West Virginia, Stati Uniti, 26101
- Camden Clark Medical Center
-
-
Wisconsin
-
Eau Claire, Wisconsin, Stati Uniti, 54701
- Marshfield Medical Center-EC Cancer Center
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Stati Uniti, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Stati Uniti, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Stati Uniti, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, Stati Uniti, 54476
- Marshfield Medical Center - Weston
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Patients must have histologically documented nasopharyngeal carcinoma (NPC) regardless of World Health Organization (WHO) classification (keratinizing squamous cell carcinoma, non-keratinizing, or basaloid squamous cell carcinoma) and regardless of association with Epstein-Barr virus (EBV) and/or human papillomavirus (HPV)
-
Recurrent, metastatic and incurable disease treated with platinum-gemcitabine and prior PD-1/L1 blockade (as first or second-line therapy)
-
Patients are eligible regardless of prior smoking history, p16 immunohistochemistry (IHC) status, PD-L1 expression status, EBV tumor status, EBV viral load at baseline, or tumor genomic alteration status
-
Patients must have at least one measurable lesion (by RECIST v1.1) which has not been previously irradiated that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions as >= 10 mm (>= 1 cm) (and short axis for nodal lesions, LN >= 15 mm) with CT scan, MRI, or calipers by clinical exam
-
Patients may have had no more than 2 prior lines of prior systemic therapy for recurrent, metastatic NPC
-
No prior VEGFR targeted therapy permitted
-
Age >= 18 years
-
Eastern Cooperative Oncology Group Performance (ECOG) performance status 0-2
-
Absolute neutrophil count (ANC) >= 1,000/mm^3
-
Hemoglobin >= 9 g/dL
-
Platelet count >= 100,000/mm^3
-
Creatinine or creatinine clearance =< 1.5 mg/dL or >= 30 Modification of Diet in Renal Disease (MDRD)
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN); except subjects with Gilbert syndrome who can have a total bilirubin < 3 mg/dL
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGT]) =< 3 x upper limit of normal (ULN)
- Up to =< 5 allowed with liver metastases
-
Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test, per institution standard, done =< 7 days prior to registration is required.
- Pregnant women are excluded from this study because nivolumab, ipilimumab, and cabozantinib are all Class C or D agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants, secondary to treatment of the mother with any of the study agents, breastfeeding should be discontinued if the mother is treated with as part of this study (in either arm)
-
No active tumor bleeding: or radiographic evidence of major blood vessel infiltration as judged by the treating investigator
-
Prior -anti-cancer therapy is allowed: Patients need to be recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1), with the exception of alopecia. Any life-threatening events clearly attributable to prior immunotherapy exposure that have a high possibility of recurring should warrant exclusion: including severe pneumonitis, grade 4 bullous dermatitis/drug reaction with eosinophilia and systemic symptoms (DRESS), neurologic events such as autoimmune encephalitis transverse myelitis, and/or myocarditis. Maintenance hormonal replacement or long-term hormonal therapy exposure is permitted.
-
No chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration. Palliative (limited-field) radiation therapy is permitted, if all of the following criteria are met:
- Repeat imaging demonstrates no new sites of bone metastases.
- The lesion being considered for palliative radiation is not a target lesion
-
-
No patients with a prior malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
-
Brain metastases allowed: Patients with treated brain metastases are eligible if follow-up brain imaging 3 weeks after central nervous system (CNS)-directed therapy shows no evidence of progression. Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial
-
For patients with evidence of chronic hepatitis B (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently receiving treatment, they are eligible if they have an undetectable HCV viral load
-
Solid organ or tissue transplant is allowed: - subsequent therapy with nivolumab increases the risk of organ/tissue rejection. Patients must be instructed that it is crucial they stay in touch with their transplant team during treatment
-
No active autoimmune disease: or history of autoimmune disease that might recur, and which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include but are not limited to patients with a history of
- Immune related neurologic disease,
- Multiple sclerosis,
- Autoimmune (demyelinating) neuropathy,
- Guillain-Barre syndrome (GBS),
- Myasthenia gravis;
- Systemic autoimmune disease such as SLE,
- Connective tissue diseases,
- Scleroderma, inflammatory bowel disease (IBD),
- Crohn's, ulcerative colitis,
- Patients with a history of toxic epidermal necrolysis (TEN),
- Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease
-
Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible
-
Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome, and psoriasis controlled with topical medication and patients with only positive serology, such as antinuclear antibodies (ANA) or anti-thyroid antibodies, should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
-
Pneumonitis should be evaluated for the nature of the disease process, need for treatment prior study treatment, and the risk of exacerbation with study treatment
-
Able to swallow oral medication: No known medical condition causing an inability to swallow oral formulations of agents
-
No condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study registration. Patients are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses > 10 mg daily prednisone are permitted. A brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by a contact allergen) is permitted
-
Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel) is prohibited. Allowed anticoagulants are the following:
- Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).
- Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
-
Concomitant use of any medications or substances that are strong inhibitors or inducers of CYP3A4 is discouraged; if unavoidable, the dose of cabozantinib on study should be adjusted accordingly. Any complementary medications (e.g., herbal supplements or traditional Chinese medicines) intended to treat the disease under study are prohibited
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Arm A (nivolumab, ipilimumab)
Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and collection of blood samples throughout the trial. |
Given IV
Altri nomi:
Undergo MRI
Altri nomi:
Given IV
Altri nomi:
Undergo collection of blood samples
Altri nomi:
Undergo CT scan
Altri nomi:
|
|
Sperimentale: Arm B (nivolumab, ipilimumab, cabozantinib)
Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 and cabozantinib S-malate PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may continue with cabozantinib S-malate after 2 years per treating investigator. Patients undergo CT or MRI and collection of blood samples throughout the trial. |
Given IV
Altri nomi:
Undergo MRI
Altri nomi:
Given PO
Altri nomi:
Given IV
Altri nomi:
Undergo collection of blood samples
Altri nomi:
Undergo CT scan
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-free survival (PFS)
Lasso di tempo: From randomization to the first of either progression or death from any cause, or censored at last known tumor assessment date, assessed up to 2 years
|
PFS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. |
From randomization to the first of either progression or death from any cause, or censored at last known tumor assessment date, assessed up to 2 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall survival (OS)
Lasso di tempo: From randomization to death from any cause, or censored at last known follow-up, assessed up to 2 years
|
OS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. |
From randomization to death from any cause, or censored at last known follow-up, assessed up to 2 years
|
|
Incidence of adverse events
Lasso di tempo: Up to 2 years
|
The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the chi-square or Fisher's exact test. |
Up to 2 years
|
|
Response by subgroups of interest
Lasso di tempo: Up to 2 years
|
Will also report and compare the overall response rate (ORR) between different subgroups of interest (primary or acquired PD-1/L1 inhibitor resistance in the prior line of therapy (further defined below), etc.). These comparisons will be done via chi-square or Fisher's exact tests. We'll also assess primary versus acquired resistance to prior PD-1 inhibition in each arm as well. While not a formal stratification, in the interim and final analysis we'll also descriptively assess these subgroups between arms as well. |
Up to 2 years
|
|
ORR
Lasso di tempo: Up to 2 years
|
The response rate will be compared via chi-square or Fisher's exact tests between the 2 treatment arms using both the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and also separately for the immune-modified RECIST criteria. |
Up to 2 years
|
|
Predictors of response
Lasso di tempo: Up to 2 years
|
Will correlate the baseline data (Epstein-Barr virus viral load, p16 immunohistochemistry status, smoking history, and PD-L1 score) with ORR data. For this analysis, logistic regression models will be assessed using the baseline data to predict binary response data. Odds ratios and 95% confidence intervals will be reported. Will also summarize the data using descriptive statistics and graphical methods. |
Up to 2 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Ari J Rosenberg, Alliance for Clinical Trials in Oncology
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie stomatognatiche
- Neoplasie per sede
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie della testa e del collo
- Neoplasie, ghiandolari ed epiteliali
- Carcinoma
- Malattie otorinolaringoiatriche
- Neoplasie faringee
- Neoplasie otorinolaringoiatriche
- Malattie nasofaringee
- Malattie faringee
- Neoplasie nasofaringee
- Carcinoma rinofaringeo
- Aminoacidi, peptidi e proteine
- Proteine
- Tecniche investigative
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Fattori biologici
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Recettori, superficie cellulare
- Proteine della membrana
- Antigeni
- Antigeni, superficie
- Biomarcatori
- Recettori, immunologici
- Antigeni, differenziazione, T-linfocita
- Antigeni, differenziazione
- Proteine del checkpoint immunitario
- Recettori costimolativi e inibitori delle cellule T.
- Nivolumab
- Ipilimumab
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
- Cabozantinib
- Antigene CTLA-4
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- NCI-2023-04469
- U10CA180821 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2023-04469 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- A092105 (Altro identificatore: CTEP)
- A092105 (Altro identificatore: Alliance for Clinical Trials in Oncology)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .